Welcome to our dedicated page for Shockwave Medical news (Ticker: SWAV), a resource for investors and traders seeking the latest updates and insights on Shockwave Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shockwave Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shockwave Medical's position in the market.
Shockwave Medical (SWAV) reported Q1 2020 revenue of $15.2 million, reflecting a 109% increase year-over-year. Gross profit rose to $9.5 million, with a gross margin of 63%. Operating expenses reached $28.5 million, up 74% due to expanded sales efforts and clinical studies. The net loss widened to $18.8 million or $0.59 per share. Amidst COVID-19 challenges, the company withdrew its annual financial guidance due to declining IVL catheter sales and uncertainty in market recovery.
Summary not available.